Business
PURA Focuses On Hemp; USMJ Expands Cannabis Ecommerce, And PJET Does Something Entirely New
PURA Focuses On Hemp; USMJ Expands Cannabis Ecommerce, And PJET Does Something Entirely New.
About this update from North American Cannabis Holdings, Inc.
[{"type":"text","content":"\n\n\n\nPURA Focuses On Hemp; USMJ Expands Cannabis Ecommerce, And PJET Does Something Entirely New\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nPURA Focuses On Hemp; USMJ Expands Cannabis Ecommerce, And PJET Does Something Entirely New\nPR Newswire\nDALLAS, Sept. 30, 2021\n\n\n\nDALLAS, Sept. 30, 2021 /PRNewswire/ -- ACI Conglomerated, the controlling shareholder of North American Cannabis Holdings, Inc. (USOTC: USMJ), Puration, Inc. (USOTC: PURA) and Priority Aviation, Inc. (USOTC: PJET), today highlighted its plans to refocus and diversify its overall strategy with the three companies.\nACI has been and continues to execute a series of transactions to update its overall business strategy in keeping with the evolving cannabis sector.\nACI is supporting PURA in the execution of its updated Farmersville Hemp Brand strategy, and likewise supporting USMJ in the execution of its cannabis industry ecommerce strategy.\nACI, in an effort to diversify, is working on the development of a new business initiative outside of the cannabis sector for PJET. PJET's new opportunity is advancing on pace, and an announcement is anticipated soon on its new business initiative.  \nDisclaimer/Safe Harbor: This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that Alkame will achieve significant sales, the failure to meet schedule or performance requirements of the Company's contracts, the Company's liquidity position, the Company's ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.\nContact:ACI...